Lumenis Receives US FDA and Japanese MHLW Clearance for Array LaserLink Pattern Scanning Device for Multi-spot Retinal Laser Treatment
Summary
“We believe Array will bring important benefits both to patients, clinicians and health care providers; and we look forward to working with the ophthalmology community to integrate our next generation technology into clinical practice.Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century.The Array LaserLink is also projected to save treatment time for clinicians and reduce patient discomfort with designed shorter pulse duration and sequential multi-spot delivery resulting in shorter laser sessions.“The introduction of the Array LaserLink device in the United States and Japan demonstrates and reaffirms Lumenis’ ongoing commitment to developing and introducing advanced ophthalmic laser products and delivery devices that grow with our customers’ needs,” said Kfir Azoulay, Vice President & General Manager of the Ophthalmology Strategic Business Unit at Lumenis.“We believe Array will bring important benefits both to patients, clinicians and health care providers; and we look forward to working with the ophthalmology community to integrate our next generation technology into clinical practice.Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century.